NI
CTMX icon

Numeric Investors’s CytomX Therapeutics CTMX Stock Holding History

Numeric Investors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$15.4M Buy
728,865
+194,000
+36% +$4.02M 0.11% 182
2017
Q3 		$9.72M Sell
534,865
-92,905
-15% -$1.45M 0.07% 260
2017
Q2 		$9.73M Buy
+627,770
New +$9.46M 0.09% 224

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Numeric Investors's CTMX Position: Q4 2017 in Review

Numeric Investors increased its CytomX Therapeutics (CTMX) stake by 36% in Q4 2017, buying an estimated $4.02M and bringing the position to 728,865 shares worth $15.4M. The position accounts for 0.11% of the portfolio, ranked #182.

Numeric Investors first reported a position in CTMX in Q2 2017 and has held it in 3 quarters since. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2017.

  • Numeric Investors held 728,865 shares of CytomX Therapeutics worth $15.4M as of Q4 2017.
  • Numeric Investors bought 194,000 CytomX Therapeutics shares in Q4 2017, an estimated $4.02M.
  • CytomX Therapeutics made up 0.11% of Numeric Investors's portfolio in Q4 2017, its #182 holding.
  • Numeric Investors first reported a position in CytomX Therapeutics in Q2 2017 and has held it in 3 quarters since.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2017.

Based on Numeric Investors's 13F filing for Q4 2017, filed 14 Feb 2018.